Clinical Trial Update: Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the combination of the monoclonal antibody 3F8 and GM-CSF (sargramostim) in young patients with high-risk, refractory o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 3F8
• sargramostim (sargramostim)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED